A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Rifampin (Rifadin IV)

Rifamycin Antibacterial class · 7 generic manufacturers · 11 ANDAs filed at FDA.

First FDA approval1989-05-25
Generic availableYes · 7 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$10.7M in CY2024 Part D spend167K claims · 64K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.625/unit
14 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.665
Across all dosage forms in distribution.
Highest NADAC
$0.686
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Rifampin used for?

Rifampin is a Rifamycin Antibacterial medication tracked in Medicare Part D.

Is there a generic for Rifampin?

Yes. 11 ANDAs filed at FDA, 7 generic manufacturers currently shipping.

How much does my plan pay for Rifampin?

Across 329 Part D plans, Rifampin averages $0.665/unit (NADAC). Lowest available: $0.625/unit. Highest in distribution: $0.686/unit.

Is Rifampin on the FDA shortage list?

Yes. Rifampin is currently listed as an active FDA shortage.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Rifamycin Antibacterial1 alternative in D1
01
Rifaximin
Brand: XIFAXAN
Lowest NADAC
0Generic mfrs
$1.80BCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (14 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.